Maxim Group reiterated coverage on SCYNEXIS with a new price target

2/17/21 2:23:39 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SCYX

Date	Price Target	Rating	Analyst